Gallery
- PM Modi visit USAOnly the mirror in my washroom and phone gallery see the crazy me : Sara KhanKarnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
Gaurav Bidhuri, 2017 World Boxing Championship bronze medallist, joined hands with the Del
- U23 World Wrestling Championship: Chirag Chikkara wins gold as India end campaign with nine medals
- FIFA president Infantino confirms at least 9 African teams for the 2026 World Cup
- Hockey, cricket, wrestling, badminton, squash axed from 2026 CWG in Glasgow
- FIFA : Over 100 female footballers urge FIFA to reconsider partnership with Saudi oil giant
- Ecuador ready to make history against Uruguay: Beccacece
Oxford Covid vaccine early stage trial shows promise: Report Last Updated : 17 Jul 2020 06:59:30 AM IST file photo A Covid-19 vaccine developed by researchers at Oxford University generated an immune response against the disease in Phase-1 trial, The Telegraph reported even as official publication of the results are awaited.
The Oxford vaccine candidate is believed to be leading the race among over 100 to find an effective protection against the disease.Oxford scientists have found that the jab triggers a response that may offer a "double defence" against SARS-CoV-2, the virus that causes Covid-19, The Telegraph report said on Wednesday.The vaccine was developed at the University of Oxford's Jenner Institute.Oxford in April announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the Covid-19 vaccine candidate.While the Phase-1 trial of the vaccine candidate began in April itself, a start of the Phase2/Phase-3 UK trial of the Oxford vaccine, named AZD1222, in about 10,000 adult volunteers, was announced in May.However, the results of the Phase-1 trial were still awaited.In June, Astrazeneca CEO Pascal Soriot told Belgian radio station Bel RTL that the Oxford vaccine will likely provide protection against the disease for one year."We think it will protect for about a year," Soriot was quoted as saying.According to a report in City A.M., AstraZeneca is aiming to deliver two billion doses of the drug by the end of the year.The drugmaker had earlier said it had reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford's Covid-19 vaccine, with deliveries starting by the end of 2020.The company completed similar agreements with the UK, the US, the Coalition for Epidemic Preparedness Innovations and Gavi the Vaccine Alliance for 700 million doses, and it agreed a licence with the Serum Institute of India for the supply of an additional one billion doses, principally for low- and middle-income countries.IANS London For Latest Updates Please-
Join us on
Follow us on
172.31.16.186